{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ng FS"],"funding":["British Heart Foundation","NHLBI NIH HHS","National Institute for Health Research (NIHR)","National Institutes of Health"],"pagination":["988-999"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8380655"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["7(8)"],"pubmed_abstract":["<h4>Objectives</h4>This first-in-human feasibility study was undertaken to translate the novel low-voltage MultiPulse Therapy (MPT) (Cardialen, Inc., Minneapolis, Minnesota), which was previously been shown to be effective in preclinical studies in terminating atrial fibrillation (AF), into clinical use.<h4>Background</h4>Current treatment options for AF, the most common arrhythmia in clinical practice, have limited success. Previous attempts at treating AF by using implantable devices have been limited by the painful nature of high-voltage shocks.<h4>Methods</h4>Forty-two patients undergoing AF ablation were recruited at 6 investigational centers worldwide. Before ablation, electrode catheters were placed in the coronary sinus, right and/or left atrium, for recording and stimulation. Afte"],"journal":["JACC. Clinical electrophysiology"],"pubmed_title":["Novel Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation."],"pmcid":["PMC8380655"],"funding_grant_id":["RG/16/3/32175","R01 HL141470","R41 HL114329","R44 HL107055","R01 HL115415","R43 HL107055"],"pubmed_authors":["Whinnett ZI","Mead RH","Winkle RA","Hocini M","Peichl P","Petru J","Shelton MB","Toman O","Ng FS","Reddy VY","Bourn DW","Neuzil P","Sharma AD","Qureshi NA","Efimov IR","Kautzner J","Haissaguerre M","Peters NS"],"additional_accession":[]},"is_claimable":false,"name":"Novel Low-Voltage MultiPulse Therapy to Terminate Atrial Fibrillation.","description":"<h4>Objectives</h4>This first-in-human feasibility study was undertaken to translate the novel low-voltage MultiPulse Therapy (MPT) (Cardialen, Inc., Minneapolis, Minnesota), which was previously been shown to be effective in preclinical studies in terminating atrial fibrillation (AF), into clinical use.<h4>Background</h4>Current treatment options for AF, the most common arrhythmia in clinical practice, have limited success. Previous attempts at treating AF by using implantable devices have been limited by the painful nature of high-voltage shocks.<h4>Methods</h4>Forty-two patients undergoing AF ablation were recruited at 6 investigational centers worldwide. Before ablation, electrode catheters were placed in the coronary sinus, right and/or left atrium, for recording and stimulation. Afte","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2025-04-19T22:58:59.868Z","creation":"2025-04-19T22:58:59.868Z"},"accession":"S-EPMC8380655","cross_references":{"pubmed":["33812836"],"doi":["10.1016/j.jacep.2020.12.014"]}}